title: Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma.
abstract: BACKGROUND Although pituitary adenoma is a malignant tumor, it can present as invasive growth in some cases. MicroRNA (miR)-26a has been found to be abnormally highly expressed in pituitary adenoma, indicating possible involvement in pathogenesis. As a known target gene of miR-26a, PLAG1 has abnormally low expression in pituitary adenoma. The correlation between miR-26a or PLAG1 expressional abnormality and occurrence of pituitary adenoma is still unknown, as is its association with invasiveness of pituitary adenoma. MATERIAL AND METHODS Pituitary adenoma tissues, including both invasive and non-invasive subtypes, were collected from our Neurosurgery Department, in parallel with normal pituitary tissues from postmortem autopsy. qRT-PCR was used to detect mRNA expression of miR-26a and PLAG1, while Western blotting was used to test PLAG1 protein expression. The correlation between miR-26a and PLAG1, and with pathological features, were analyzed. ROC analysis revealed the utility of miR-26a and PLAG1 in differential diagnosis of invasive/non-invasive pituitary tumors and in analyzing their effects on patient prognosis. RESULTS MiR-26a was remarkably upregulated in pituitary tumors, while PLAG1 was downregulated, especially in invasive pituitary tumors. miR-26a and PLAG1 had higher diagnostic values for differentiating between invasive and non-invasive pituitary tumors (AUC=0.889 and 0.818, respectively). Those patients with miR-26 overexpression and PLAG1 downregulation had unfavorable prognosis. miR-26 and PLAG1 are independent factors affecting patient diagnosis. CONCLUSIONS MiR-26a can facilitate occurrence of pituitary tumor and invasiveness, probably via inhibiting PLAG1 expression.
authors.affiliation: Department of Clinical Laboratory, Yantaishan Hospital, Yantai, Shandong, China (mainland).
authors.forename: ChuanTing
authors.initials: C
authors.lastname: Yu
authors.affiliation: Department of Clinical Laboratory, Yantaishan Hospital, Yantai, Shandong, China (mainland).
authors.forename: JiXia
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Clinical Laboratory, Yantaishan Hospital, Yantai, Shandong, China (mainland).
authors.forename: FengNan
authors.initials: F
authors.lastname: Sun
authors.affiliation: Department of Clinical Laboratory, Yantaishan Hospital, Yantai, Shandong, China (mainland).
authors.forename: JinPeng
authors.initials: J
authors.lastname: Cui
authors.affiliation: Department of Clinical Laboratory, Yantaishan Hospital, Yantai, Shandong, China (mainland).
authors.forename: HuaLi
authors.initials: H
authors.lastname: Fang
authors.affiliation: Department of Endocrinology, Yantaishan Hospital, Yantai, Shandong, China (mainland).
authors.forename: GuoLang
authors.initials: G
authors.lastname: Sui
mesh_terms: D000328:Adult; D000368:Aged; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology*; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012372:ROC Curve; D012044:Regression Analysis; D012307:Risk Factors; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D004268:DNA-Binding Proteins; D035683:MicroRNAs; D012333:RNA, Messenger; C528163:MIRN26 microRNA, human; C104382:PLAG1 protein, human